)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Rezolute
Rezolute (RZLT) investor relations material
Rezolute Q4 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2026 earnings summary24 Sep, 2026
Executive summary
Reported Q4 and full year 2026 financial results, highlighting ongoing clinical progress in ultra-rare hypoglycemia indications.
Provided updates on Phase 3 studies for tumor HI (upLIFT) and congenital HI (sunRIZE), including interim and extension data.
Financial highlights
Cash, cash equivalents, and investments totaled $107.8 million as of June 30, 2026, down from $167.9 million a year earlier.
Q4 2026 net loss was $20.5 million, compared to $24.4 million in Q4 2025.
Full year 2026 net loss was $77.6 million, up from $74.4 million in 2025.
R&D expenses for Q4 2026 were $14.9 million (down from $20.9 million YoY); full year R&D was $53.8 million (down from $61.5 million YoY).
G&A expenses for Q4 2026 were $6.7 million (up from $5.0 million YoY); full year G&A was $29.2 million (up from $18.4 million YoY).
Outlook and guidance
Topline results from the upLIFT study in tumor HI expected before the end of 2026.
Awaiting FDA feedback on the sunRIZE congenital HI study; potential for further regulatory discussions.
Commercial preparations for ersodetug ongoing, with increased professional fees in anticipation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Rezolute
- Late-stage antibody therapy targets refractory hypoglycemia in HI, with $1B+ global potential.RZLT
Corporate presentation - Late-stage antibody therapy targets refractory hypoglycemia in HI, with $1B+ market potential.RZLTCorporate presentation
- Pivotal data and regulatory milestones support dual BLA filings and strong market prospects in 2025.RZLTJefferies Global Healthcare Conference 2026
- Phase 3 data showed strong efficacy for ersodetug in HI; net loss narrowed as R&D costs fell.RZLTQ3 2026
- Ersodetug advances in Phase 3 for HI, targeting a $1B+ rare disease market with FDA engagement.RZLTCorporate presentation
- Late-stage antibody therapy targets severe hypoglycemia in rare hyperinsulinism, with $1B+ potential.RZLTCorporate presentation
- Net loss widened to $22.8M; cash and investments at $132.9M, with key trials ongoing.RZLTQ2 2026
- All annual meeting proposals, including share and incentive plan increases, were approved.RZLTAGM 2024
- Antibody therapy for hyperinsulinism shows strong efficacy and targets rare disease markets.RZLTGuggenheim Securities Inaugural Healthcare Innovation Conference
Next Rezolute earnings date
Q1 20275 Nov, 2026
Rezolute
Next Rezolute earnings date
Q1 20275 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage